OTCBB:RZLT

Rezolute Stock News

*Your capital is at risk

$4.58

+0.580 (+14.50%)

At Close: Jun 03, 2026

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

08:30am, Tuesday, 12'th Jan 2021

RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME

featured in The Global Fintech Index 2020 as the top Fintech company of the country.